Severe dystrophic cardiomyopathy caused by the enteroviral protease 2A-mediated C-terminal dystrophin cleavage fragment

Science Translational Medicine

Volumn 7, Issue 294, 2015, Pages

  Barnabei, Matthew S ^a   Sjaastad, Frances V ^a   Townsend, DeWayne ^a   Bedada, Fikru B ^a   Metzger, Joseph M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; PROTEASE 2A; UNCLASSIFIED DRUG; VIRUS PROTEIN; GLYCOPROTEIN; PEPTIDE FRAGMENT; PEPTIDE HYDROLASE;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CARDIOMYOPATHY; CARDIOTOXICITY; CELLULAR DISTRIBUTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART STRESS; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONTENT; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SARCOLEMMA; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CARDIAC MUSCLE; CELL MEMBRANE; CHEMISTRY; ENTEROVIRUS; ENZYMOLOGY; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGICAL STRESS; SURVIVAL ANALYSIS; TRANSGENIC MOUSE;

ANIMALS; CARDIOMYOPATHIES; CELL MEMBRANE; DISEASE SUSCEPTIBILITY; DYSTROPHIN; ENTEROVIRUS; GLYCOPROTEINS; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; STRESS, PHYSIOLOGICAL; SURVIVAL ANALYSIS;

EID: 84934325466     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa4804     Document Type: Article

References (36)

1. A. M. Feldman, D. McNamara, Myocarditis. N. Engl. J. Med. 343, 1388-1398 (2000).
2. L. T. Cooper Jr., Myocarditis. N. Engl. J. Med. 360, 1526-1538 (2009).
3. L. Andréoletti, L. Ventéo, F. Douche-Aourik, F. Canas, G. Lorin de la Grandmaison, J. Jacques, H. Moret, N. Jovenin, J. F. Mosnier, M. Matta, S. Duband, M. Pluot, B. Pozzetto, T. Bourlet, Active Coxsackieviral B infection is associated with disruption of dystrophin in endomyocardial tissue of patients who died suddenly of acute myocardial infarction. J. Am. Coll. Cardiol. 50, 2207-2214 (2007).
4. J. A. Towbin, M. Vatta, Myocardial infarction, viral infection, and the cytoskeleton. J. Am. Coll. Cardiol. 50, 2215-2217 (2007).
5. J. M. Ervasti, K. P. Campbell, A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 809-823 (1993).
6. I. N. Rybakova, J. R. Patel, J. M. Ervasti, The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J. Cell Biol. 150, 1209-1214 (2000).
7. S. Yasuda, D. Townsend, D. E. Michele, E. G. Favre, S. M. Day, J. M. Metzger, Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 436, 1025-1029 (2005).
8. D. Townsend, S. Yasuda, J. Metzger, Cardiomyopathy of Duchenne muscular dystrophy: Pathogenesis and prospect of membrane sealants as a new therapeutic approach. Expert Rev. Cardiovasc. Ther. 5, 99-109 (2007).
9. J. S. Chamberlain, Gene therapy of muscular dystrophy. Hum. Mol. Genet. 11, 2355-2362 (2002).
10. C. Badorff, N. Berkely, S. Mehrotra, J. W. Talhouk, R. E. Rhoads, K. U. Knowlton, Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J. Biol. Chem. 275, 11191-11197 (2000).
11. C. Badorff, G. H. Lee, B. J. Lamphear, M. E. Martone, K. P. Campbell, R. E. Rhoads, K. U. Knowlton, Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5, 320-326 (1999).
12. D.Xiong,T.Yajima,B.K.Lim,A.Stenbit,A.Dublin,N.D.Dalton,D.Summers-Torres, J. D. Molkentin, H. Duplain, R. Wessely, J. Chen, K. U. Knowlton, Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 115, 94-102 (2007).
13. K. U. Knowlton, CVB infection and mechanisms of viral cardiomyopathy. Curr. Top. Microbiol. Immunol. 323, 315-335 (2008).
14. B. K. Lim, A. K. Peter, D. Xiong, A. Narezkina, A. Yung, N. D. Dalton, K. K. Hwang, T. Yajima, J. Chen, K. U. Knowlton, Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy. J. Clin. Invest. 123, 5146-5151 (2013).
15. N. E. Bowles, K. R. Bowles, J. A. Towbin, The "final common pathway" hypothesis and inherited cardiovascular disease. The role of cytoskeletal proteins in dilated cardiomyopathy. Herz 25, 168-175 (2000).
16. E. M. McNally, H. MacLeod, Therapy insight: Cardiovascular complications associated with muscular dystrophies. Nat. Clin. Pract. Cardiovasc. Med. 2, 301-308 (2005).
17. G. A. Cox, Y. Sunada, K. P. Campbell, J. S. Chamberlain, Dp71 can restore the dystrophinassociated glycoprotein complex in muscle but fails to prevent dystrophy. Nat. Genet. 8, 333-339 (1994).
18. L. M. Judge, A. L. Arnett, G. B. Banks, J. S. Chamberlain, Expression of the dystrophin isoform Dp116 preserves functional muscle mass and extends lifespan without preventing dystrophy in severely dystrophic mice. Hum. Mol. Genet. 20, 4978-4990 (2011).
19. K. J. Amann, B. A. Renley, J. M. Ervasti, A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. J. Biol. Chem. 273, 28419-28423 (1998).
20. I. N. Rybakova, K. J. Amann, J. M. Ervasti, A new model for the interaction of dystrophin with F-actin. J. Cell Biol. 135, 661-672 (1996).
21. D. Townsend, S. Yasuda, E. McNally, J. M. Metzger, Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex. FASEB J. 25, 3106-3114 (2011).
22. A. Heydemann, E. M. McNally, Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy. Trends Cardiovasc. Med. 17, 55-59 (2007).
23. D. Townsend, M. J. Blankinship, J. M. Allen, P. Gregorevic, J. S. Chamberlain, J. M. Metzger, Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol. Ther. 15, 1086-1092 (2007).
24. D. Townsend, S. Yasuda, S. Li, J. S. Chamberlain, J. M. Metzger, Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol. Ther. 16, 832-835 (2008).
25. G. Danialou, A. S. Comtois, R. Dudley, G. Karpati, G. Vincent, C. Des Rosiers, B. J. Petrof, Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J. 15, 1655-1657 (2001).
26. A. Ahmad, M. Brinson, B. L. Hodges, J. S. Chamberlain, A. Amalfitano, Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum. Mol. Genet. 9, 2507-2515 (2000).
27. T. Yajima, K. U. Knowlton, Viral myocarditis: From the perspective of the virus. Circulation 119, 2615-2624 (2009).
28. K. U. Knowlton, B. K. Lim, Viral myocarditis: Is infection of the heart required? J. Am. Coll. Cardiol. 53, 1227-1228 (2009).
29. A. P. Weir, E. A. Burton, G. Harrod, K. E. Davies, A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. J. Biol. Chem. 277, 45285-45290 (2002).
30. A. O. Gramolini, G. Karpati, B. J. Jasmin, Discordant expression of utrophin and its transcript in human and mouse skeletal muscles. J. Neuropathol. Exp. Neurol. 58, 235-244 (1999).
31. K. A. Kleopa, A. Drousiotou, E. Mavrikiou, A. Ormiston, T. Kyriakides, Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy. Hum. Mol. Genet. 15, 1623-1628 (2006).
32. G. H. Lee, C. Badorff, K. U. Knowlton, Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy. Circ. Res. 87, 489-495 (2000).
33. T. Toyo-Oka, T. Kawada, J. Nakata, H. Xie, M. Urabe, F. Masui, T. Ebisawa, A. Tezuka, K. Iwasawa, T. Nakajima, Y. Uehara, H. Kumagai, S. Kostin, J. Schaper, M. Nakazawa, K. Ozawa, Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: A scheme for the progression of cardiac dysfunction. Proc. Natl. Acad. Sci. U.S.A. 101, 7381-7385 (2004).
34. C. Badorff, B. Fichtlscherer, R. E. Rhoads, A. M. Zeiher, A. Muelsch, S. Dimmeler, K. U. Knowlton, Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy. Circulation 102, 2276-2281 (2000).
35. S. F. Phelps, M. A. Hauser, N. M. Cole, J. A. Rafael, R. T. Hinkle, J. A. Faulkner, J. S. Chamberlain, Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet. 4, 1251-1258 (1995).
36. S. M. Day, M. V. Westfall, E. V. Fomicheva, K. Hoyer, S. Yasuda, N. C. La Cross, L. G. D'Alecy, J. S. Ingwall, J. M. Metzger, Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat. Med. 12, 181-189 (2006).